Skip to main content
CMPX logo

Compass Therapeutics, Inc.

CMPXNASDAQHealthcareBiotechnology

$0.86Today:- (-)1Y −78.95%

As of Oct 16, 2026 close

Market cap
$167.50M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.82$6.88
Volume (live)
-
Avg. volume (3M)
5.92M

Compass Therapeutics (CMPX) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Compass Therapeutics used $49.14M of cash in operating activities and spent $25.00K on capital expenditures. That left free cash flow of −$49.17M. It repurchased $1.03M of its own shares.

Compass Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Compass Therapeutics, Inc. (CMPX) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Mar 2020Mar 2019
Operating Activities
Net Income-66.49-49.38-42.49-39.23-82.18-29.50-34.74-38.29
Depreciation & Amortization0.280.590.700.781.622.402.121.92
Deferred Income Tax0.000.000.000.000.000.840.11-0.26
Stock Based Compensation8.378.566.125.334.034.020.920.66
Change in Working Capital9.18-4.14-2.91-1.266.25-3.60-0.262.17
Change in Accounts Payable-0.66-1.840.712.52-0.190.43-1.100.99
Change in Other Working Capital4.75-6.075.56-6.690.04-4.030.841.18
Other Operating Activities-0.48-0.49-2.040.250.04-0.960.120.12
Net Cash from Operating Activities-49.14-44.86-40.62-34.13-19.67-26.80-31.74-33.68
Investing Activities
Capital Expenditures-0.03-0.04-0.03-0.21-1.57-0.11-0.47-2.02
Acquisitions0.000.000.000.000.000.140.000.00
Purchases of Investments-194.56-88.16-155.42-200.120.000.000.000.00
Sales/Maturities of Investments101.28134.97182.4148.960.000.000.000.00
Other Investing Activities0.000.000.000.18-0.200.000.000.00
Net Cash from Investing Activities-93.3146.7726.97-151.20-1.770.04-0.47-2.02
Financing Activities
Debt Repayment0.000.000.000.00-9.380.000.000.00
Common Stock Issued139.2718.113.1976.25128.2760.480.0049.08
Common Stock Repurchased-1.03-0.23-0.160.000.000.000.000.00
Other Financing Activities-8.64-0.54-0.09-0.50-0.28-6.320.0464.03
Net Cash from Financing Activities129.6117.342.9475.76118.6148.540.0464.03
Summary
Effect of Forex Changes on Cash0.000.000.000.000.000.00-0.040.00
Net Change in Cash-12.8419.82-10.72-109.5797.1821.77-32.2128.33
Cash at Beginning of Period44.0524.2334.95144.5147.3425.5757.7729.44
Cash at End of Period31.2143.4824.2334.95144.5147.3425.5757.77
Free Cash Flow-49.17-44.90-40.65-34.34-21.23-26.91-32.21-35.70
Supplemental Disclosures
Interest Paid----0.370.85--

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Compass Therapeutics Cash Flow

What is Compass Therapeutics's free cash flow?

Compass Therapeutics had negative free cash flow of $49.17M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$49.14M minus $25.00K of capital expenditures.

How much does Compass Therapeutics spend on capital expenditures?

Compass Therapeutics spent $25.00K on capital expenditures in fiscal 2025, compared with $44.00K a year earlier.

Does Compass Therapeutics pay dividends or buy back shares?

Yes. In fiscal 2025 Compass Therapeutics returned $1.03M in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition